Advances in the Treatment of Alzheimer’s Disease: Benefits of Dual Cholinesterase Inhibition

Publisher： Karger

E-ISSN： 1421-9913|47|1|64-70

ISSN： 0014-3022

Source： European Neurology, Vol.47, Iss.1, 2002-01, pp. : 64-70

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Economic Analysis of Galantamine, a Cholinesterase Inhibitor, in the Treatment of Patients with Mild to Moderate Alzheimer’s Disease in The Netherlands

By  

Dementia and Geriatric Cognitive Disorders, Vol. 14, Iss. 2, 2002-07 ,pp. : 84-89

Karger

Access to resources Recommend Favorite

Treatment Effects of Therapeutic Cholinesterase Inhibitors on Visuospatial Processing in Alzheimer’s Disease: A Longitudinal Functional MRI Study

By  

Dementia and Geriatric Cognitive Disorders, Vol. 29, Iss. 2, 2010-03 ,pp. : 176-188

Karger

Access to resources Recommend Favorite

Treatment of Alzheimer’s Disease with Clioquinol

By  

Dementia and Geriatric Cognitive Disorders, Vol. 12, Iss. 6, 2001-10 ,pp. : 408-414

Karger

Access to resources Recommend Favorite

Rivastigmine in the Treatment of Alzheimer’s Disease

By  

European Neurology, Vol. 46, Iss. 2, 2001-08 ,pp. : 110-110

Karger

Access to resources Recommend Favorite

Galantamine: Additional Benefits to Patients with Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 11, Iss. 1, 2000-09 ,pp. : 19-27

Karger

Access to resources Recommend Favorite